TRCT
GMAB icon

Tower Research Capital (TRC)’s Genmab GMAB Stock Holding History

Tower Research Capital (TRC)’s Portfolio GMAB Stock Details GMAB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$18.6K Sell
695
-109,964
-99% -$3.3M ﹤0.01% 3523
2025
Q4 		$3.41M Buy
110,659
+109,647
+10,835% +$3.42M 0.08% 212
2025
Q3 		$31K Sell
1,012
-45,641
-98% -$1.11M ﹤0.01% 2905
2025
Q2 		$964K Buy
46,653
+45,618
+4,408% +$936K 0.03% 567
2025
Q1 		$20.3K Sell
1,035
-11,482
-92% -$241K ﹤0.01% 2952
2024
Q4 		$261K Buy
12,517
+5,785
+86% +$127K 0.01% 1528
2024
Q3 		$164K Sell
6,732
-25,694
-79% -$687K ﹤0.01% 1802
2024
Q2 		$815K Buy
32,426
+28,212
+669% +$800K 0.01% 925
2024
Q1 		$126K Sell
4,214
-4,004
-49% -$118K ﹤0.01% 1709
2023
Q4 		$262K Buy
8,218
+6,504
+379% +$204K ﹤0.01% 1880
2023
Q3 		$60.5K Sell
1,714
-34,933
-95% -$1.33M ﹤0.01% 2385
2023
Q2 		$1.39M Buy
36,647
+31,398
+598% +$1.25M 0.05% 346
2023
Q1 		$198K Buy
5,249
+3,498
+200% +$134K 0.01% 1378
2022
Q4 		$74K Sell
1,751
-1,648
-48% -$67.9K ﹤0.01% 2060
2022
Q3 		$109K Sell
3,399
-9,165
-73% -$322K ﹤0.01% 2490
2022
Q2 		$409K Buy
12,564
+7,936
+171% +$257K 0.01% 1263
2022
Q1 		$167K Sell
4,628
-56
-1% -$1.92K ﹤0.01% 1855
2021
Q4 		$185K Sell
4,684
-4,561
-49% -$190K ﹤0.01% 1833
2021
Q3 		$404K Buy
9,245
+8,413
+1,011% +$378K 0.01% 1152
2021
Q2 		$34K Sell
832
-2,089
-72% -$80.6K ﹤0.01% 3348
2021
Q1 		$96K Buy
+2,921
New +$110K ﹤0.01% 2614
2020
Q4 		– Sell
-1,725
Closed -$63K – 5237
2020
Q3 		$63K Buy
+1,725
New +$62.4K ﹤0.01% 3438
2020
Q2 		– Sell
-100
Closed -$2K – 4832
2020
Q1 		$2K Buy
+100
New +$2.23K ﹤0.01% 2583
2019
Q4 		– Sell
-50
Closed -$1K – 3825
2019
Q3 		$1K Buy
+50
New +$985 ﹤0.01% 3860

Other funds holding GMAB

OAG
Orbis Allan Gray Hamilton, Bermuda $23.7B AUM 65.43% 1-Year Est. Return
AllianceBernstein
AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return
PBA
Paradigm Biocapital Advisors New York $4.89B AUM 251.12% 1-Year Est. Return
Arrowstreet Capital
Arrowstreet Capital Boston, Massachusetts $185B AUM 39.58% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
HL
Harding Loevner Bridgewater, New Jersey $9.72B AUM 22.38% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
First Trust Advisors
First Trust Advisors Wheaton, Illinois $140B AUM 27.84% 1-Year Est. Return

Tower Research Capital (TRC)'s GMAB Position: Q1 2026 in Review

Tower Research Capital (TRC) reduced its Genmab (GMAB) stake by 99% in Q1 2026, selling an estimated $3.3M and leaving 695 shares worth $18.6K. The position accounts for ﹤0.01% of the portfolio, ranked #3523.

Tower Research Capital (TRC) first reported a position in GMAB in Q3 2019 and has held it in 24 quarters since. The position peaked at $3.41M in Q4 2025. 272 funds tracked by Wall St. Rank hold GMAB as of Q1 2026.

  • Tower Research Capital (TRC) held 695 shares of Genmab worth $18.6K as of Q1 2026.
  • Tower Research Capital (TRC) sold 109,964 Genmab shares in Q1 2026, an estimated $3.3M.
  • Genmab made up ﹤0.01% of Tower Research Capital (TRC)'s portfolio in Q1 2026, its #3523 holding.
  • Tower Research Capital (TRC) first reported a position in Genmab in Q3 2019 and has held it in 24 quarters since.
  • Tower Research Capital (TRC)'s Genmab position peaked at $3.41M in Q4 2025.
  • 272 funds tracked by Wall St. Rank held Genmab as of Q1 2026.

Based on Tower Research Capital (TRC)'s 13F filing for Q1 2026, filed 15 May 2026.